Annovis Bio Resumes Treatment of Patients in Ongoing Phase 2a Study in Alzheimer’s Disease After COVID-Related Delay

By WebmasterOctober 29, 2020November 1st, 2024No Comments

Annovis Bio Resumes Treatment of Patients in Ongoing Phase 2a Study in Alzheimer’s Disease After COVID-Related Delay

Previous PostMebias Discovery Receives Grant from NIDA to Advance MEB 1170 as an Analgesic Drug Candidate for the Prevention and Treatment of Opioid Use Disorder
Next PostRelmada Therapeutics Expands R&D Team, Appoints Paolo Manfredi, M.D., as Acting Chief Scientific Officer, Marco Pappagallo, M.D., as Acting Chief Medical Officer and Updates R&D Milestones